Achieving long-term survival in extensive-stage SCLC: a case report and mini literature review

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 73(1), 17–48 (2023).
   PubMed Web of Science ®Google Scholar
• Megyesfalvi Z, Gay CM, Popper H et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J. Clin. 73(6), 620–652 (2023).
   PubMed Web of Science ®Google Scholar
• Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current diagnosis and management of small-cell lung cancer. Mayo Clin. Proc. 94(8), 1599–1622 (2019).
   PubMed Web of Science ®Google Scholar
• Krpina K, Vranic S, Tomic K, Samarzija M, Baticic L. Small cell lung carcinoma: current diagnosis, biomarkers, and treatment options with future perspectives. Biomedicines 11(7), 1982 (2023).
   PubMed Web of Science ®Google Scholar
• Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years–an analysis of 1,714 consecutive patients. J. Clin. Oncol. 13(5), 1215–1220 (1995).
   PubMed Web of Science ®Google Scholar
• Rudin CM, Kim HR, Navarro A et al. OA12.06 first-line pembrolizumab or placebo combined with etoposide and platinum for ES-SCLC: KEYNOTE-604 long-term follow-up results. Journal of Thoracic Oncology 17(9), S33–S34 (2022).
   Web of Science ®Google Scholar
• Paz-Ares L, Chen Y, Reinmuth N et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 7(2), 100408 (2022).
   PubMed Web of Science ®Google Scholar
• OA01.04. five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: Imbrella a extension study results. https://cattendee.abstractsonline.com/meeting/10925/Session/83
   Google Scholar
• Schild SE, Sio TT, Daniels TB, Chun SG, Rades D. Prophylactic Cranial irradiation for extensive small-cell lung cancer. J. Oncol. Pract. 13(11), 732–738 (2017).
   PubMed Web of Science ®Google Scholar
• Lu H, Jiang Z. Advances in antiangiogenic treatment of small-cell lung cancer. Onco. Targets Ther. 10, 353–359 (2017).
   PubMed Web of Science ®Google Scholar
• Cheng Y, Han L, Wu L et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA 328(12), 1223–1232 (2022).
   PubMed Web of Science ®Google Scholar
• Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19(12), 775–790 (2022).
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat. Rev. Cancer 17(12), 725–737 (2017).
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Behera M, Chen Z et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J. Thorac. Oncol. 7(5), 866–872 (2012).
   PubMed Web of Science ®Google Scholar
• Bergdorf K, Ferguson DC, Mehrad M, Ely K, Stricker T, Weiss VL. Papillary thyroid carcinoma behavior: clues in the tumor microenvironment. Endocr. Relat. Cancer 26(6), 601–614 (2019).
   PubMed Web of Science ®Google Scholar
• Filetti S, Durante C, Hartl D et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann. Oncol. 30(12), 1856–1883 (2019).
   PubMed Web of Science ®Google Scholar
• Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat. Rev. Clin. Oncol. 14(9), 549–561 (2017).
   PubMed Web of Science ®Google Scholar
• Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat. Rev. Dis. Primers 7(1), 3 (2021).
   PubMed Web of Science ®Google Scholar
• Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J. Thorac. Oncol. 4(1), 37–43 (2009).
   PubMed Web of Science ®Google Scholar
• Sun JM, Choi YL, Ji JH et al. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. Ann. Oncol. 26(1), 161–166 (2015).
   PubMed Web of Science ®Google Scholar
• Zhang X, Guo M, Fan J et al. Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. Cancer Biomark 16(3), 415–423 (2016).
   PubMed Web of Science ®Google Scholar
• Frampton JE. Atezolizumab: a review in extensive-stage SCLC. Drugs 80(15), 1587–1594 (2020).
   PubMed Web of Science ®Google Scholar
• Genestreti G, Tiseo M, Kenmotsu H et al. Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge: a multi-institutional retrospective analysis. Clin. Lung Cancer 16(6), e223–e228 (2015).
   PubMed Web of Science ®Google Scholar
• Plaja A, Moran T, Carcereny E et al. Small-cell lung cancer long-term survivor patients: how to find a needle in a haystack? Int. J. Mol. Sci. 22(24), 13508 (2021).
   PubMed Web of Science ®Google Scholar
• Bortolotti S, Angelucci S, Montemurro L et al. Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance. Cancers (Basel) 15(3), 990 (2023).
   PubMed Web of Science ®Google Scholar
• Roviello G, Generali D. Is there a place for bevacizumab in patients with extensive-stage small cell lung cancer? Curr. Cancer Drug Targets 16(3), 209–214 (2016).
   PubMed Web of Science ®Google Scholar
• Montanino A, Manzo A, Carillio G et al. Angiogenesis Inhibitors in Small Cell Lung Cancer. Front Oncol. 11, 655316 (2021).
   PubMedGoogle Scholar
• Zhu YJ, Zhang HB, Liu YH et al. Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer. Oncol. Lett. 14(1), 655–664 (2017).
   PubMed Web of Science ®Google Scholar
• Spigel DR, Townley PM, Waterhouse DM et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J. Clin. Oncol. 29(16), 2215–2222 (2011).
   PubMed Web of Science ®Google Scholar
• Tiseo M, Boni L, Ambrosio F et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J. Clin. Oncol. 35(12), 1281–1287 (2017).
   PubMed Web of Science ®Google Scholar
• Zhou ZT, Zhou FX, Wei Q, Zou LY, Qin BF, Peng XS. Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer. Cancer Chemother. Pharmacol. 68(4), 1027–1032 (2011).
   PubMed Web of Science ®Google Scholar
• Abdelraouf F, Smit E, Hasan B et al. Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a ‘chemosensitive’ relapse: a single-arm phase II study (EORTC-08061). Eur. J. Cancer 54, 35–39 (2016).
   PubMed Web of Science ®Google Scholar
• Sharma N, Pennell N, Nickolich M et al. Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Invest. New Drugs 32(2), 362–368 (2014).
   PubMed Web of Science ®Google Scholar
• Sanborn RE, Patel JD, Masters GA et al. A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113. Cancer 123(2), 303–311 (2017).
   PubMed Web of Science ®Google Scholar
• Lee SM, Woll PJ, Rudd R et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J. Natl Cancer Inst. 101(15), 1049–1057 (2009).
   PubMedGoogle Scholar
• Ready NE, Pang HH, Gu L et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II Study-CALGB 30504 (Alliance). J. Clin. Oncol. 33(15), 1660–1665 (2015).
   PubMedGoogle Scholar
• Ramalingam SS, Belani CP, Mack PC et al. Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J. Thorac. Oncol. 5(8), 1279–1284 (2010).
   PubMed Web of Science ®Google Scholar
• Han JY, Kim HY, Lim KY, Hwangbo B, Lee JS. A phase II study of nintedanib in patients with relapsed small cell lung cancer. Lung Cancer 96, 108–112 (2016).
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang Q, Li K et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. Br. J. Cancer 125(3), 366–371 (2021).
   PubMed Web of Science ®Google Scholar
• Shi J, Cheng Y, Wang Q et al. Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202). Front Med. 16(5), 766–772 (2022).
   PubMed Web of Science ®Google Scholar
• Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer. Cancer Med. 12(5), 5372–5383 (2023).
   PubMed Web of Science ®Google Scholar
• OA01.03 Benmelstobart with anlotinib plus chemotherapy as first-line therapy for ES-SCLC: a randomized, double-blind, phase III trial. https://cattendee.abstractsonline.com/meeting/10925/Session/83
   Google Scholar
• Liu SV, Reck M, Mansfield AS et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J. Clin. Oncol. 39(6), 619–630 (2021).
   PubMed Web of Science ®Google Scholar
• Goldman JW, Dvorkin M, Chen Y et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 22(1), 51–65 (2021).
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou C, Yao W et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23(6), 739–747 (2022).
   PubMed Web of Science ®Google Scholar
• Rudin CM, Awad MM, Navarro A et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J. Clin. Oncol. 38(21), 2369–2379 (2020).
   PubMed Web of Science ®Google Scholar
• Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as front-line therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. doi: 10.1200/JCO.2020.38.15_suppl.9000
   Google Scholar
• Pujol JL, Greillier L, Audigier-Valette C et al. A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 trial. J. Thorac. Oncol. 14(5), 903–913 (2019).
   PubMed Web of Science ®Google Scholar
• Rittberg R, Banerji S, Kim JO, Rathod S, Dawe DE. Treatment and prevention of brain metastases in small cell lung cancer. Am. J. Clin. Oncol. 44(12), 629–638 (2021).
   PubMed Web of Science ®Google Scholar
• Wang W, Hodkinson P, Mclaren F et al. Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate. Int. J. Cancer 131(6), E928–E937 (2012).
   PubMed Web of Science ®Google Scholar
• Muppa P, Parrilha Terra SBS, Sharma A et al. Immune cell infiltration may be a key determinant of long-term survival in small cell lung cancer. J. Thorac. Oncol. 14(7), 1286–1295 (2019).
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Ricken G, Wilhelm D et al. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). J. Neurooncol. 130(1), 19–29 (2016).
   PubMed Web of Science ®Google Scholar
• Koyama K, Kagamu H, Miura S et al. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin. Cancer Res. 14(21), 6770–6779 (2008).
   PubMed Web of Science ®Google Scholar
• Gay CM, Stewart CA, Park EM et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(3), 346–360; e347 (2021).
   PubMed Web of Science ®Google Scholar
• Rudin CM, Balli D, Lai WV et al. Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation. J. Thorac. Oncol. 18(9), 1222–1232 (2023).
   PubMed Web of Science ®Google Scholar